Results 31 to 40 of about 3,974 (218)

Dermoscopy of juvenile circumscribed pityriasis rubra pilaris

Indian Dermatology Online Journal, 2018
Pragya A Nair, Niral Sheth
doaj   +2 more sources

A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report

SAGE Open Medical Case Reports, 2022
Classic adult pityriasis rubra pilaris is a severe papulosquamous disease that tends to resolve in 3–5 years but can have a devastating impact on patients while active.
Celina DeBiasio, Janelle Cyr, Yasmine Ayroud, Steven J Glassman   +3 more
doaj   +1 more source

Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination

Skin Health and Disease, 2023
Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination.
Ya‐ting Liu, Shang‐shang Wang
doaj   +1 more source

Pityriasis rubra pilaris

Dermatology Online Journal, 2003
Pityriasis rubra pilaris is a chronic, papulosquamous dermatosis of unclear etiology. The case of a 61-year-old man with pityriasis rubra pilaris is presented. The clinical forms, histopathologic features, and treatment options of pityriasis rubra pilaris are reviewed.
N. Cammarota, T. M. Lotti, J. Hergocova
openaire   +7 more sources

Morbus‐Grover‐artige Muster in der Frühphase der Pityriasis rubra pilaris [PDF]

J Dtsch Dermatol Ges
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 2, Page 231-233, February 2025.
Hoffmann J, Durani B, Hartschuh W.
europepmc   +2 more sources

Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris. [PDF]

Life (Basel)
Potestio L, D'Agostino M, Portarapillo A, Esposito V, Tommasino N, Salsano A, Guerriero L, Martora F, Megna M.   +8 more
europepmc   +2 more sources

Targeting IL-1 controls refractory pityriasis rubra pilaris. [PDF]

Sci Adv
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis ...
Schmauch E, Severin Y, Xing X, Mangold A, Conrad C, Johansen P, Kahlenberg JM, Mellett M, Navarini A, Nobbe S, Sarkar MK, Satyam A, Tsoi LC, French LE, Nilsson J, Linna-Kuosmanen S, Kaikkonen MU, Snijder B, Kellis M, Gudjonsson JE, Tsokos GC, Contassot E, Kolios AGA.   +22 more
europepmc   +3 more sources

Loss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris. [PDF]

Nat Commun
Shi P, Chen W, Lyu X, Wang Z, Li W, Jia F, Zheng C, Liu T, Wang C, Zhang Y, Mi Z, Sun Y, Chen X, Chen S, Zhou G, Liu Y, Lin Y, Bai F, Sun Q, Ogese MO, Yu Q, Liu J, Liu H, Zhang F.   +23 more
europepmc   +3 more sources

Pityriasis Rubra Pilaris refractory to ustekinumab successfully treated with guselkumab [PDF]

JEADV Clinical Practice, Volume 3, Issue 4, Page 1240-1243, September 2024.
Capsule SummaryPityriasis Rubra Pilaris (PRP) is a rare inflammatory skin condition that often poses diagnostic and therapeutic challenges, particularly in refractory cases. Ustekinumab and guselkumab, both targeting the Th‐17 axis, are well established treatment options in psoriasis patients. Emerging evidence, supported by Th‐17 axis insights in PRP,
João Teixeira, Ana Luísa Matos, André Aparício‐Martins, Joana Calvão, Hugo Oliveira   +4 more
openalex   +2 more sources

Late onset pityriasis rubra pilaris type IV treated with low-dose acitretin [PDF]

, 2016
Pityriasis rubra pilaris is a chronic inflammatory dermatosis of unknown etiology and great clinical variability. It has been divided into six categories.
Carvalho, S., Mota, F., Sanches, M., Selores, M.   +3 more
core   +1 more source